The establishment of a comprehensive model based on the expression of tumor PD‐L1 and the characteristics of immune cell infiltration can better predict which patients can benefit from anti‐PD‐1/ PD‐L1 monoclonal antibody therapy. This evidence concerns the gene PDCD1 and neoplasm.